Media.Player

Enhancing the anti-cancer efficacy of cisplatin by Drp1 inhibition

Detailed Technology Description

None

*Abstract

BackgroundCisplatin is among the most active chemotherapeutic agents, widely used for treatment against a spectrum of solid human tumors such as testicular, ovarian, bladder, cervical, head and neck, small-cell and non-small-cell lung cancers, esophageal, and stomach.. However, several side effects such as kidney toxicity and the inherent resistance of tumors to cisplatin often undermine its therapeutic potential.Technology DescriptionInvestigators have demonstrated that using a protein inhibitor induces cell cycle arrest in an aggressive breast cancer cell line. In addition to pharmacological inhibition it was found that genetic down regulation via protein-specific siRNA was another way to target this protein for inhibition. The combinaton of the inhibitor with cisplatin significantly enhanced the anti-cancer efficacy of cisplatin in breast cancer cell lines. Cisplatin and the inhibitor appear to act synergistically to kill breast cancer cell lines.Applications* Combination therapy of cisplatin and the protein inhibitor may be used to treat a variety of tumors including cisplatin resistant cancer cells* Enhances anticancer drug efficacy by disrupting mitochondrial dynamicsAdvantages* Novel therapy to enhance the treatment of solid tumors* Combination therapy may allow cisplatin doses to be reduced thereby alleviating the dose-related side effects while maintaining the necessary anti-tumor activityStage of Development* In vitro dataProvisional Patent Application filed

*Principal Investigator

Name: Wei Qian

Department: Med-Pharmacology and Chemical Biology

Name: Bennett Van Houten

Department: Med-Pharmacology and Chemical Biology

Country/Region

USA